Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00359892
Status:
COMPLETED
Last Update Posted:
2012-08-06
First Post:
2006-08-02
Brief Title:
Safety and Efficacy of Obatoclax Mesylate GX15-070MS in the Treatment of Hodgkins Lymphoma
Sponsor:
Gemin X
Organization:
Teva Branded Pharmaceutical Products RD Inc
Study Overview
Official Title:
A Multi-Center Open-Label Phase II Study of Single-Agent GX15-070MS Administered as a 24-Hour Infusion Every 2 Weeks to Patients With Relapsed or Refractory Hodgkins Lymphoma
Status:
COMPLETED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present Obatoclax is designed to restore apoptosis through inhibition of the Bcl-2 family of proteins thereby reinstating the natural process of cell death that is often inhibited in cancer cells
This is a multi-center open-label Phase II study of single-agent obatoclax administered in 2-week cycles as a 24-hour infusion every 2 weeks at a fixed dose of 60 mg to patients with relapsed or refractory Hodgkins Lymphoma Infusions may be administered on an out-patient basis No investigational or commercial agents or therapies other than those described in the protocol may be administered with the intent to treat the patients malignancy Supportive care measures including those directed at controlling symptoms resulting from Hodgkins Lymphoma blood products growth factor etc are allowed
This is a multi-center open-label Phase II study of single-agent obatoclax administered in 2-week cycles as a 24-hour infusion every 2 weeks at a fixed dose of 60 mg to patients with relapsed or refractory Hodgkins Lymphoma Infusions may be administered on an out-patient basis No investigational or commercial agents or therapies other than those described in the protocol may be administered with the intent to treat the patients malignancy Supportive care measures including those directed at controlling symptoms resulting from Hodgkins Lymphoma blood products growth factor etc are allowed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None